STEEPLE: Safety and efficacy of enoxaparin in percutaneous coronary intervention patients

September 06, 2005

Results of the STEEPLE trial to be announced at the Hotline session today by Pr Gilles Montalescot, the trial's principal investigator, have the potential to revise current procedural anticoagulation using standard uncertain ACT-driven unfractionated heparin (UFH) in percutaneous coronary intervention (PCI). STEEPLE (Safety and efficacy of enoxaparin in elective percutaneous coronary intervention: an international randomized evaluation) is the first large scale, prospective, open label, randomized, controlled clinical trial comparing intravenous (iv) enoxaparin and UFH in the catheterization laboratory.

The study was conducted with 3,528 patients from 124 sites and nine countries in Europe, North America and Australasia undergoing non emergent PCI randomized to iv enoxaparin (0.5 mg/kg or 0.75 mg/kg) or an activated clotting time (ACT)-adjusted UFH regimen, stratified by the operator's choice of glycoprotein (GP) IIb/IIIa inhibitor use. The primary endpoint was to evaluate the safety of iv enoxaparin compared with iv UFH measuring the incidence of non-coronary artery bypass graft (CABG)-related major and minor bleeding up to 48 hours following index PCI. The main secondary efficacy endpoint was the percentage of patients reaching target anticoagulation levels at the beginning and end of the procedure. A secondary efficacy composite endpoint consisted of non-CABG-major bleeding up to 48 hours, all cause mortality, non-fatal myocardial infarction, or urgent target vessel revascularization at 30 days. The data may confirm earlier results from small and non comparative trials that have shown enoxaparin to be simple and effective and not associated with excessive bleeding in patients undergoing PCI with or without GP IIb/IIIa inhibitors.1
-end-
1: Borentain M, Montalescot G, Bouzamondo A, Choussat R, Hulot JS, Lechat P. Catheter Cardiovasc Interv 2005;65:212-21.

European Society of Cardiology

Related Percutaneous Coronary Intervention Articles from Brightsurf:

A bypass route for the coronary vessels in the heart?
When the heart develops, some of its coronary blood vessels develop from cells lining the inner surface of the heart's ventricular chambers (endocardium).

Amgen announces new FOURIER analysis showing Repatha® (evolocumab) reduced cardiovascular events in patients with prior percutaneous intervention at AHA 2020
Amgen (NASDAQ:AMGN) today announced a new analysis from the Repatha® (evolocumab) cardiovascular (CV) outcomes study (FOURIER) that evaluated the effectiveness of Repatha in atherosclerotic cardiovascular disease (ASCVD) patients on statin therapy with prior percutaneous coronary intervention (PCI), also known as coronary angioplasty.

Ultrasound-guided percutaneous needle biopsy excellent for small pleural lesions diagnosis
According to an open-access article in ARRS' American Journal of Roentgenology, ultrasound (US)-guided percutaneous pleural needle biopsy (PCPNB) has excellent diagnostic accuracy for small pleural lesions.

For toddlers with autism, more intervention hours are not necessarily better
Two prominent early intervention models for toddlers with autism show a very similar impact, whether delivered at 15-hours or 25-hours per week intensities, a UC Davis MIND Institute study has found.

Minimally invasive percutaneous treatment for osteoid osteoma of the spine
Osteoid osteomas are benign but painful bone-forming tumors usually involving long bones, with localization at the spine in 10-20% of the cases.

SCAI issues position statement on the performance of percutaneous coronary intervention in ambulatory surgical centers
The Society for Cardiovascular Angiography and Interventions (SCAI) today issued a position statement on the performance of percutaneous coronary intervention (PCI) in ambulatory surgical centers (ASCs).

SCAI releases official position statement on optimal percutaneous interventional therapy for complex coronary artery disease
The Society for Cardiovascular Angiography and Interventions (SCAI) has published a position statement addressing optimal percutaneous coronary intervention (PCI) treatment of patients with complex coronary artery disease (CAD).

Does coronary microvascular spasm exist?
In a new publication from Cardiovascular Innovations and Applications; Fabian Guenther, Andreas Seitz, Valeria Martínez Pereyra, Raffi Bekeredjian, Udo Sechtem and Peter Ong from the Department of Cardiology, Robert-Bosch-Krankenhaus, Stuttgart, Germany consider whether coronary microvascular spasm exists.

Impact of postdilation on intervention success and MACE
In a new publication from Cardiovascular Innovations and Applications; DOI https://doi.org/10.15212/CVIA.2019.0564, the authors consider the impact of postdilation on intervention success and long-term major adverse cardiovascular events (MACE) among patients with acute coronary syndromes.

The relationship between mean platelet volume and in-hospital mortality in geriatric patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention
In the current issue of Cardiovascular Innovations and Applications volume 4, issue 2, pp.

Read More: Percutaneous Coronary Intervention News and Percutaneous Coronary Intervention Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.